Respiratory Medicine and Allergology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden; and.
Department of Medicine, Blekinge Hospital, Karlskrona, Sweden.
Ann Am Thorac Soc. 2022 Oct;19(10):1677-1686. doi: 10.1513/AnnalsATS.202110-1174OC.
Long-term oxygen therapy (LTOT) is prescribed for at least 15 hours per day and often used by patients for several years, but knowledge is limited regarding adverse effects, risk exposures, and health-related quality of life (HrQoL) among those treated. To determine the prevalence of adverse effects, smoking, and alcohol consumption and their relations to HrQoL among patients treated with LTOT. This was a cross-sectional survey of a randomized sample of adults with ongoing LTOT in the Swedish National Registry for Respiratory Failure (Swedevox). Patient characteristics and the prevalence of 26 prespecified adverse effects, smoking, and alcohol consumption, were compared between respondents with better and worse HrQoL on the chronic obstructive pulmonary disease assessment test. A total of 151 respondents were included (mean age, 74.7 yr [standard deviation, 8.6 yr]; 58.9% women; median LTOT duration, 2.2 yr [interquartile range, 1.0-3.8 yr]). Characteristics upon starting LTOT were similar between respondents and nonrespondents. Active smoking was very rare ( = 4, 2.6%). For alcohol use, 67.2% of participants reported no consumption during an average week, whereas risk use was reported by 25.8% of men and 16.9% of women. The most prevalent adverse effects were reduced mobility or physical activity (70.9%), dry mouth (69.5%), congestion or nasal drip (61.6%), increased tiredness (57.0%), and dry nose (53.0%). Patients with higher numbers of total and systemic adverse effects experienced worse HrQoL, whereas no associations were found for smoking status or alcohol consumption. The majority (54.8%) of adverse effects were untreated and unreported to health professionals. Adverse effects are common among patients with LTOT and are associated with worse HrQoL. As the majority of adverse effects had not been discussed or treated, structured assessment and management of risk exposures and adverse effects is warranted.
长期氧疗(LTOT)规定每天至少 15 小时,患者通常使用数年,但对于接受治疗的患者的不良反应、风险暴露和健康相关生活质量(HrQoL)知之甚少。本研究旨在确定 LTOT 治疗患者的不良反应、吸烟和饮酒的患病率及其与 HrQoL 的关系。这是一项在瑞典呼吸衰竭国家登记处(Swedevox)中接受持续 LTOT 的成年人随机样本的横断面调查。通过比较慢性阻塞性肺疾病评估测试(CAT)得分更好和更差的患者的患者特征和 26 种预先规定的不良反应、吸烟和饮酒的患病率。共纳入 151 名应答者(平均年龄 74.7 岁[标准差 8.6 岁];58.9%女性;中位 LTOT 持续时间 2.2 年[四分位间距 1.0-3.8 年])。开始 LTOT 时的特征在应答者和非应答者之间相似。主动吸烟非常罕见( = 4,2.6%)。关于饮酒,67.2%的参与者报告在平均一周内无饮酒,而男性中有 25.8%和女性中有 16.9%报告存在风险饮酒。最常见的不良反应是活动受限或体力活动减少(70.9%)、口干(69.5%)、充血或鼻后滴注(61.6%)、疲劳增加(57.0%)和鼻干(53.0%)。总不良反应和全身性不良反应数量较多的患者的 HrQoL 较差,而吸烟状况或饮酒与不良相关。未报告给卫生专业人员的不良反应和未治疗的不良反应占大多数(54.8%)。LTOT 患者的不良反应很常见,与较差的 HrQoL 相关。由于大多数不良反应尚未讨论或治疗,因此需要对风险暴露和不良反应进行结构化评估和管理。